Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia

Sex: All

Ages: 18 Years – 65 Years

Healthy volunteers: No

Phase: NA

Enrollment: 18

Sponsor: University of Colorado, Denver

Summary

Levetiracetam (LEV: (S)-α-ethyl-2-oxo-pyrrolidine acetamide) is an anticonvulsant/antiepileptic drug. The specific aim of this study is to assess the efficacy of low-dose LEV in reducing hippocampal activity in schizophrenia. The investigators also hypothesize that LEV will improve neurocognition in participants with schizophrenia.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of schizophrenia or schizoaffective disorder * Good general health * Normal vital signs (blood pressure, pulse, cardiac, pulmonary, abdominal, neurological exam) * Normal renal function (as assessed by a metabolic panel at screening if results current within three months are not already available) Exclusion Criteria: 1. Substance abuse 2. Significant neurological disorders 3. Significant head trauma/injury 4. Left-handedness 5. Pregnancy 6. MRI-specific exclusion criteria (e.g., claustrophobia, weight \> 450lbs, metal in the body)

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT02647437). StuddyBuddy aggregates publicly available trial information.